// App-Quantinova.ai

PB2329 : Tissue Factor Pathway Inhibitor, Activated Protein C Resistance and Risk of Venous Thrombosis Associated with Menopausal Hormone Therapy

Researchers

Presenter

  • D. Khialani

Principal Investigators

  • S. Vasan

  • M. Cushman

  • A. Dahm

  • P. Morten Sandset

  • J. Rossouw

  • A. van Hylckama Vlieg

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • Fred Hutchinson Cancer Research Center, Seattle, WA, United States

  • University of Vermond Medical Center, Vermont, United States

  • University of Oslo, Oslo, Norway

  • Women's Health Initiative Branch, National Heart, Lung and Blood Institute, Bethesda, United States

Locations

  • Netherlands

  • United States

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Adenomatous Polyposis Coli

  • Nucleoside diphosphate kinase A

  • Coagulation Factor III, Tissue Factor

  • Tissue factor pathway inhibitor

Drug/Treatment

  • Medroxyprogesterone

  • Protein C

  • anti-thymocyte equine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved